Prostate Cancer Screening Rivals Breast Cancer Detection, Study Finds

Prostate cancer screening performs on par with breast cancer screening in detecting significant cancers and reducing deaths, according to a meta-analysis unveiled at the European Association of Urology 2026 Congress.

Researchers analyzed data from nearly 40,000 men in Germany’s PROBASE trial who received PSA testing at age 45 or 50, comparing results to over 2.8 million women in national mammography programs.

While PSA testing followed by MRI produced more false positives than mammography, biopsies were far more likely to detect significant cancer-50-68% in men versus 10% in women. Invasive cancer detection rates were nearly identical.

Tobias Nordström of Karolinska Institute said the findings validate current prostate screening approaches. Sigrid Carlsson from the German Cancer Research Centre noted that non-aggressive cancers are better managed in prostate care due to established active surveillance, minimizing overtreatment.

Cost-effectiveness compared to current opportunistic screening is now under review.